From hearts to tumors: How pulsed electric field technology is making the leap into oncology

Galvanize Therapeutics has enrolled the first patient in its PROPEL Registry, an observational study designed to assess real-world use of its Aliya® Pulsed Electric Field (PEF) ablation system in soft tissue tumors. The milestone underscores how a technology first proven in the heart is now making its way into cancer care.

The registry, expected to enroll up to 1,000 patients across 50 U.S. centers, will track outcomes for lung, liver, and metastatic lesions over a period of 24 months. The first procedure was completed at Duke University Medical Center, marking the beginning of what Galvanize hopes will be a large-scale validation of PEF in oncology.

Why pulsed electric field ablation is expanding from cardiac arrhythmia treatment to solid tumor therapy

Pulsed electric field ablation first drew attention in cardiology, where its precision in treating atrial fibrillation helped minimize damage to surrounding tissue compared with thermal techniques. Instead of relying on heat, PEF uses high-voltage electrical pulses that selectively induce cell death while preserving the extracellular matrix and nearby structures such as vessels and airways.

That tissue-sparing feature has made PEF attractive in oncology, particularly for tumors located in complex or sensitive regions where heat-based ablation poses risks. The Aliya system can be applied percutaneously or endoscopically, giving clinicians flexibility in accessing hard-to-reach lesions. Early studies also suggest the approach may release tumor antigens, potentially activating the immune system and opening the door for combination strategies with immunotherapies.

For Galvanize, the launch of PROPEL is a way to expand Aliya’s clinical footprint beyond controlled trials. Company executives said the registry will capture procedural data, patient outcomes, and physician feedback, offering a clearer picture of how PEF can be integrated into everyday practice.

The move mirrors the trajectory of PEF in cardiology, where adoption accelerated once real-world data confirmed safety and efficacy across large patient groups. Analysts following the medical device sector have drawn parallels, noting that oncology may represent the next disruptive frontier for PEF after its success in arrhythmia treatment.

How could the PROPEL Registry accelerate clinical adoption and increase investor confidence in pulsed electric field oncology?

By enrolling a broad and diverse patient population, the PROPEL Registry may generate the scale of evidence that payers and clinicians require before adopting new ablation technologies. Observational registries have become an increasingly common pathway for device makers to demonstrate value, particularly when randomized trials are not immediately feasible.

For patients, wider adoption of PEF could mean more treatment options in cases where traditional ablation or radiation are unsuitable. For investors, the registry signals that Galvanize sees commercial potential in oncology, a field with growing demand for minimally invasive, tissue-preserving treatments. Market watchers have suggested that positive outcomes could position Galvanize as an attractive partner or acquisition target for larger medical device companies seeking oncology growth.

The global tumor ablation market was valued at around USD 1.5 billion in 2024, with double-digit growth expected. If PEF establishes itself alongside thermal ablation, radiofrequency, and microwave options, analysts believe it could secure a meaningful share of that expanding segment.

What long-term opportunities could pulsed electric field ablation create for the oncology treatment landscape and for medtech competition?

Galvanize is not alone in pushing pulsed electric field beyond cardiology. Other device developers and academic centers are also exploring its potential in cancer care. While details of competing programs are less public, industry observers expect the space to become increasingly competitive as clinical data accumulates.

For now, Galvanize has the advantage of a large registry and a clear strategy to build physician confidence through evidence generation. If the PROPEL Registry delivers consistent safety and efficacy results, it could accelerate Aliya’s pathway toward guideline inclusion and broader reimbursement support.

Beyond Galvanize, the implications for oncology are substantial. PEF’s potential to ablate tumors in sensitive locations, while sparing critical tissue, offers new hope for patients with limited options. If its immunomodulatory properties are further validated, it may also serve as a complementary approach alongside immunotherapies, expanding its relevance beyond focal ablation. For the medtech sector, success in this space could spark consolidation, with larger companies moving to acquire smaller innovators once proof of adoption is demonstrated.

The leap from hearts to tumors demonstrates how medical technologies can cross therapeutic boundaries, finding new relevance in areas with pressing unmet needs. For pulsed electric field ablation, oncology may represent its most transformative chapter yet.